Li Cuiping, Dong Bing, Xu Xiaomeng, Li Yuewen, Wang Yan, Li Xingmei
Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Qiqihar Medical College, No. 27 Taishujie, Tiefeng District, Qiqihar, 161000 China.
Cytotechnology. 2021 Jun;73(3):363-372. doi: 10.1007/s10616-021-00463-6. Epub 2021 Apr 3.
Ovarian cancer is one of the leading lethal gynecological cancers, causing serious harm to the health of female populations. Growing studies emphasize that lncRNAs serve as significant regulators in the tumorigenesis and evolution of numerous malignancies, including ovarian cancer. Recently, the oncogenic activity of lncRNA ARAP1-AS1 has been justified in a variety of cancers. However, the potential function of ARAP1-AS1 in ovarian cancer development is still unclear. Herein, we firstly revealed the expression profile of ARAP1-AS1 in ovarian cancer. Compared to normal samples and cells, upregulation of ARAP1-AS1 was observed in tissues and cells of ovarian cancer. Therewith, it was disclosed that knockdown of ARAP1-AS1 alleviated the carcinogenicity of ovarian cancer cells. Besides, our findings delineated that ARAP1-AS1 silence inhibited the expression of oncogene PLAGL2. Considering that ARAP1-AS1 was principally expressed in the the cytoplasm of ovarian cancer cells, we speculated that ARAP1-AS1 facilitated ovarian cancer progression via functioning as a ceRNA. Further investigations indicated that ARAP1-AS1 promoted PLAGL2 expression by competitively binding with miR-4735-3p. Of note, ARAP1-AS1 contributed to the malignant phenotypes of ovarian cancer cells through modulation of miR-4735-3p/PLAGL2 axis, revealing ARAP1-AS1 as a promising therapeutic target for ovarian cancer patients.
卵巢癌是致死率最高的妇科癌症之一，对女性群体的健康造成严重危害。越来越多的研究强调，长链非编码RNA（lncRNAs）在包括卵巢癌在内的多种恶性肿瘤的发生和发展过程中发挥着重要的调节作用。最近，lncRNA ARAP1-AS1的致癌活性在多种癌症中得到了证实。然而，ARAP1-AS1在卵巢癌发展中的潜在作用仍不清楚。在此，我们首先揭示了ARAP1-AS1在卵巢癌中的表达谱。与正常样本和细胞相比，在卵巢癌组织和细胞中观察到ARAP1-AS1上调。据此，研究发现敲低ARAP1-AS1可减轻卵巢癌细胞的致癌性。此外，我们的研究结果表明，ARAP1-AS1沉默会抑制癌基因PLAGL2的表达。鉴于ARAP1-AS1主要在卵巢癌细胞的细胞质中表达，我们推测ARAP1-AS1通过作为竞争性内源RNA（ceRNA）发挥作用促进卵巢癌进展。进一步研究表明，ARAP1-AS1通过与miR-4735-3p竞争性结合来促进PLAGL2表达。值得注意的是，ARAP1-AS1通过调节miR-4735-3p/PLAGL2轴促成卵巢癌细胞的恶性表型，这表明ARAP1-AS1有望成为卵巢癌患者的治疗靶点。
